Is MyMD Pharmaceuticals, Inc. overvalued or undervalued?

As of 11 May 2020, MyMD Pharmaceuticals, Inc. has moved from a valuation grade of risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued given its financial metrics, including a price-to-book value of 0.17 and an EV to EBITDA ratio of 0.42. Notably, the return on equity (ROE) stands at a concerning -57.42%, reflecting the company's struggles in generating returns for shareholders.
In comparison to its peers, MyMD Pharmaceuticals shows a stark contrast with Regulus Therapeutics, Inc., which has a P/E ratio of -11.9462, and Corbus Pharmaceuticals Holdings, Inc., with an EV to EBITDA of 0.5170. The overall peer group indicates that MyMD Pharmaceuticals is not only underperforming but also lacks the financial metrics to justify its current valuation. The company's stock has significantly underperformed against the S&P 500, with a year-to-date decline of 88.00%, further reinforcing the notion that it is overvalued in the current market environment.